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adult T cell leukemia cells through suppression
of C/EBPα signaling
Tiejun Zhao1,2*, Aaron Coutts2,4, Lingling Xu1, Juntao Yu1, Koichi Ohshima3 and Masao Matsuoka2*Abstract
Background: Human T-cell leukemia virus type 1 (HTLV-1) is an oncogenic retrovirus etiologically associated with
adult T-cell leukemia (ATL). The HTLV-1 bZIP factor (HBZ), which is encoded by minus strand of provirus, is
expressed in all ATL cases and supports the proliferation of ATL cells. However, the precise mechanism of growth
promoting activity of HBZ is poorly understood.
Results: In this study, we showed that HBZ suppressed C/EBPα signaling activation induced by either Tax or
C/EBPα. As mechanisms of HBZ-mediated C/EBPα inhibition, we found that HBZ physically interacted with C/EBPα
and diminished its DNA binding capacity. Luciferase and immunoprecipitation assays revealed that HBZ repressed
C/EBPα activation in a Smad3-dependent manner. In addition, C/EBPα was overexpressed in HTLV-1 infected cell
lines and fresh ATL cases. HBZ was able to induce C/EBPα transcription by enhancing its promoter activity. Finally,
HBZ selectively modulated the expression of C/EBPα target genes, leading to the impairment of C/EBPα-mediated
cell growth suppression.
Conclusion: HBZ, by suppressing C/EBPα signaling, supports the proliferation of HTLV-1 infected cells, which is
thought to be critical for oncogenesis.
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Human T-cell leukemia virus type 1 (HTLV-1) is the
causative agent of adult T-cell leukemia (ATL) [1,2].
HTLV-1 encodes several regulatory (tax and rex) and
accessory (p12, p13 and p30) genes in the pX region
located between the env and 3’ long terminal repeat
(LTR) [3]. Among the viral genes, Tax is thought to play
a central role in the pathogenesis of HTLV-1 [4]. Yet the
expression of Tax cannot be detected in ~60% of fresh
ATL cases due to epigenetic modifications or deletion of
the 5’LTR [5]. In contrast, the HTLV-1 bZIP factor
(HBZ), which is encoded by the minus strand of the
HTLV-1 genome, is expressed in all ATL cases and
supports the proliferation of HTLV-1 infected cells [6-8].* Correspondence: tjzhao@zjnu.cn; mmatsuok@virus.kyoto-u.ac.jp
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reproduction in any medium, provided the orHTLV-2, a type of retrovirus which is similar with
HTLV-1, encodes an antisense protein (APH-2) using
the minus strand of its genome. However, APH-2 does
not seem to promote cell proliferation [9,10]. HBZ was
reported to repress Tax-mediated transactivation of viral
transcription from the HTLV-1 5’LTR [11]. Moreover,
HBZ dysregulated multiple cellular signalings including
the classical pathway of NF-κB, TGF-β, AP-1, and the
Wnt pathways, which is likely to contribute to viral per-
sistence and clonal expansion of infected cells [12-15].
The CCAAT/enhancer binding protein (C/EBP) family
of proteins represents a critical group of bZIP transcription
factors that are key to the regulation of cell proliferation,
development, and immune responses [16,17]. Dysregulated
C/EBP signaling is intimately associated with tumorigenesis
and viral diseases [18]. Furthermore, the ability of C/EBPs
to direct cellular fate is thought to depend on the presence
of specific collaborating transcription factors, and allows
C/EBPs to act as both tumor suppressors and tumor
promoters under different conditions [17]. C/EBPα, thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 HBZ suppressed C/EBPα signaling. (A) HBZ repressed
C/EBPα-induced transcriptional activation. Jurkat cells were
cotransfected with pC/EBP-Luc (0.5 μg), phRL-TK (10 ng),
pME18Sneo-HBZ (0, 0.5, 1, and 2 μg), and pCMV-Tag-C/EBPα (1 μg).
After 48 hours, the cells were harvested and analyzed for luciferase
activity. (B) HBZ impaired the suppressive effect of C/EBPα on
HTLV-1 LTR activation. Jurkat cells were cotransfected with pLTR-Luc
(0.5 μg), phRL-TK (10 ng), and pME18Sneo-HBZ (2 μg), pCG-Tax
(1 μg), together with pCMV-Tag-C/EBPα (1 μg). At 48 hours after
transfection, a dual luciferase reporter assay was performed. All the
data shown are relative values of firefly luciferase normalized to
Renilla luciferase and expressed as mean of a triplicate set of
experiments ± SD. *P < 0.05; **P < 0.01.
Zhao et al. Retrovirology 2013, 10:159 Page 2 of 13
http://www.retrovirology.com/content/10/1/159founding member of this family, has been demonstrated to
be important for differentiation of several cell types [19].
On the other hand, C/EBPα emerged as an important
negative regulator of cell proliferation [20]. Thus, most
tumors have evolved distinct strategies to attenuate
C/EBPα function [17,21]. Known mechanisms of C/EBPα
suppression in cancer cells include (1) transcriptional
downregulation of CEBPA expression; (2) point mutations
and deletions in C/EBPα; and (3) inhibition of C/EBPα
transcriptional activation through protein-protein inter-
action. However, normal C/EBPα is overexpressed in B-
cell precursor acute lymphoblastic leukemia (BCP-ALL),
and inhibits apoptosis by upregulating bcl-2 and FLIP
expression [22,23]. It suggested that C/EBPα may exhibit
oncogenic as well as tumour suppressor properties in
human leukaemogenesis.
In ATL, Tax has been shown to bind to CCAAT bind-
ing proteins such as nuclear factor YB subunit (NF-YB)
and C/EBPβ [24]. Through its association with NF-YB,
Tax activates the major histocompatibility complex class
II (MHC-II) promoter [24]. Additionally, C/EBPβ was
capable of inhibiting Tax-dependent transactivation of
the HTLV-1 LTR, as well as efficiently decreasing Tax
synthesis from an infectious HTLV-1 molecular clone
[25]. On the other hand, expression of Tax increases
binding of C/EBPβ to and activates the IL-1β promoter
[26]. Interestingly, previously published microarray data
showed that the CEBPA gene was overexpressed in adult
T-cell leukemia cells [27,28]. It is thus likely that the
dysregulated C/EBP signaling pathway may play a role
in ATL.
Although regulation of C/EBP signaling by Tax has
been reported, little is known about whether other viral
proteins affect C/EBP signaling. In the present study, we
found that HBZ suppressed C/EBP signaling by inter-
acting with C/EBPα, resulting in the impairment of
C/EBPα-mediated cell growth suppression. This might
account for why HBZ supports the proliferation of
HTLV-1 infected cells.
Results
HBZ suppresses C/EBPα signaling
To investigate the effect of HBZ on the C/EBP signaling
pathway, Jurkat cells were cotransfected with expression
vectors of C/EBPα and HBZ along with a C/EBP-res-
ponsive reporter: C/EBP-Luc. As shown in Figure 1A,
C/EBPα enhanced the transcription of luciferase, while
HBZ inhibited C/EBPα-mediated C/EBP signaling acti-
vation in a dose-dependent manner. It was reported that
C/EBP transcription factors dysregulated transcription
from long terminal repeat [25]. We therefore analyzed
whether HBZ could modulate HTLV-1 promoter activity
through C/EBP signaling. Consistent with previous re-
ports, overexpression of C/EBPα inhibited Tax-mediatedHTLV-1 LTR activation [29]. Moreover, HBZ overcame
the repression of HTLV-1 viral transcription by C/EBPα
(Figure 1B). These results collectively indicate that HBZ
impairs the function of C/EBPα.
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Accumulating evidences show that HBZ dysregulates
signaling pathways in ATL by associating with multiple
transcriptional factors [8,12-15,30,31]. To clarify the
molecular mechanism by which HBZ suppresses the
C/EBPα transcriptional response, we investigated whether
HBZ can physically interact with C/EBPα. FLAG-tagged
C/EBPα and mycHis-tagged HBZ were cotransfected into
293T cells, and an immunoprecipitation assay was per-
formed. Figure 2A illustrates that HBZ interacted with
C/EBPα. The HBZ-C/EBPα association was further
analyzed by confocal microscopy. Cotransfected cells
showed nuclear spots representing co-localization of
HBZ and C/EBPα protein (Figure 2B). To investigate
whether HBZ influences the ability of C/EBPα to bind
its DNA target, we performed a ChIP assay in 293T
cells that were cotransfected with C/EBP-Luc reporter
























Figure 2 HBZ interacted with C/EBPα protein. (A) HBZ interacted with C
FLAG-C/EBPα. After 48 hours, cell lysates were subjected to immunoprecipi
(B) HBZ co-localized with C/EBPα. Hela cells were transfected with mycHis-
antibody (ii). C/EBPα was detected using anti–Flag-biotin and secondary St
shown (iii). (C) HBZ decreased C/EBPα’s DNA binding capability. After trans
293T cells were chromatin immunoprecipitated by anti-FLAG antibody. The
the pC/EBP-Luc specific primers. Expression of HBZ and C/EBPα was detect
of C/EBPα. 293T cells were transfected with expression vector of C/EBPα an
subjected to immunoblotting.The ChIP assay detected the association of C/EBPα
with its responsive elements, while HBZ dramatically
decreased C/EBPα’s DNA binding capability (Figure 2C).
Previous reports showed that HBZ decreased the expres-
sion level of its associated proteins [12,13]. Therefore, we
analyzed whether HBZ could also affect the expression of
C/EBPα. As shown in Figure 2D, HBZ did not induce
C/EBPα protein degradation even at high doses. In
addition, C/EBPα did not influence HBZ expression
(Additional file 1: Figure S1). These observations suggest
that HBZ represses C/EBPα-induced transcription through
physical association between HBZ and C/EBPα.
HBZ depends on Smad3 to inhibit C/EBPα-mediated
transcription
Several reports have indicated that Smad3 interacted
with C/EBP and repressed C/EBP transactivation func-








/EBPα. 293T cells were cotransfected with mycHis-HBZ together with
tation using anti–c-Myc followed by immunoblotting using anti-FLAG.
HBZ and FLAG-C/EBPα. HBZ was detected using anti–MYC Cy3
reptavidin-Alexa 488 antibody (i). The overlay of HBZ and C/EBPα is
fection with mycHis-HBZ, FLAG-C/EBPα, and pC/EBPα-Luc for 48 hours,
precipitated DNAs and 1% of the input cell lysates were amplified by
ed by Western blot (bottom panel). (D) HBZ could not repress the level
d various amounts of mycHis-HBZ. After 48 hours, the cell lysates were
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Smad3 is required for HBZ to suppress C/EBPα, we
analyzed the effect of SIS3, an inhibitor of Smad3, on
the ability of HBZ to inhibit C/EBPα transcriptional
activity. Figure 3A demonstrates that SIS3 impaired the
ability of HBZ to suppress transcriptional activity
through C/EBP-responsive elements. In addition, when
Smad3 expression was inhibited by siRNA, the HBZ-
mediated suppression of C/EBPα activity was partially
restored, indicating that Smad3 functions to suppress- + + + + +
- - + - + -
- - - + - +















































Figure 3 Smad3 was involved in the suppression of C/EBPα signaling
hours after SIS3 (5 μM) treatment, Jurkat cells were cotransfected with pC/E
pCMV-Tag-C/EBPα (0.5 μg). Luciferase activity was measured 48 hours after
mediated suppression of C/EBPα. HepG2 cells were transfected with expres
mRNA expression was analyzed by RT-PCR. Luciferase activity was measure
a ternary complex. mycHis-HBZ, FLAG-Smad3, and HA-C/EBPα were cotrans
immunoprecipitation with anti-FLAG agarose affinity gel and anti-HA antibC/EBPα signaling along with HBZ (Figure 3B). We next
explored whether HBZ, C/EBPα, and Smad3 could form
a ternary complex. Vectors expressing mycHis-HBZ,
FLAG-Smad3, and HA-C/EBPα were cotransfected into
293T cells, and a serial immunoprecipitation assay was
performed. As shown in Figure 3C, and Additional file 2:
Figure S2, we detected a specific ternary complex only
when the three components were coexpressed. These
results together suggest that HBZ inhibits C/EBPα signal-
ing by forming complexes of HBZ-Smad3-C/EBPα.- + + + +
- - + + +
- - - + -










































by HBZ. (A) SIS3 overcame HBZ-induced repression of C/EBPα. Six
BP-Luc (0.5 μg), phRL-TK (10 ng), pME18Sneo-HBZ (2 μg), and
transfection. (B) Reducing SMAD3 expression by siRNA recovered HBZ
sion vectors together with Smad3 siRNA or control siRNA. SMAD3
d 48 hours after transfection. (C) HBZ, Smad3, and C/EBPα could form
fected into 293T cells. Ternary complexes were detected by sequential
ody, followed by immunoblotting with the His antibody.
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Next, we evaluated the region of HBZ responsible for
the inhibition of C/EBP signaling. To this end, we tested
the HBZ deletion mutants shown in Figure 4A. Figure 4B
demonstrated that wild-type HBZ down-regulated
C/EBPα-mediated transcriptional responses. Compared
with other mutants, only the HBZ ΔCD mutant exhibited
suppressive activity. We mapped the region of HBZ inter-
acting with C/EBPα in detail. As shown in Figure 4C, full-
length HBZ and three of its deletion mutants (HBZ-ΔAD,FLAG-C/EBP
mycHis-HBZ -




















Figure 4 Domains of HBZ responsible for the suppression of C/EBPα
study. Characteristic domains of HBZ are indicated as follows: activation do
(bZIP). (B) Analysis of HBZ deletion mutants for their effect on C/EBPα-med
phRL-TK, pCMV-Tag-C/EBPα and pME18Sneo-HBZ mutants. After 48 hours,
**P < 0.01. (C) Determination of the region of HBZ responsible for the inter
mycHis-HBZ mutants together with the FLAG-C/EBPα. Cell lysates were sub
immunoblotting using anti-FLAG. (D) The schema of C/EBPα deletion mutant
indicated. (E) Mapping the region of the C/EBPα protein necessary for interac
full-length or mutant FLAG-C/EBPα. At 48 hours after transfection, total cell lysaHBZ-ΔbZIP, and HBZ-ΔCD) associated with C/EBPα,
while HBZ-AD and HBZ-bZIP have no binding capability.
These results collectively indicate that both the AD and
bZIP domains in HBZ were necessary for suppression of
the C/EBPα pathway. To define which part of C/EBPα
binds HBZ, we performed a co-immunoprecipitation
assay with C/EBPα mutants (Figure 4D). The C/EBPα-
ΔbZIP mutant, which did not contain the bZIP domain,
was incapable of interacting with HBZ. However, the
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signaling. (A) Schematic diagram of HBZ and its mutants used in this
main (AD), central domain (CD), and basic leucine zipper domain
iated signaling. Jurkat cells were cotransfected with pC/EBP-Luc,
the cells were harvested and analyzed for luciferase activity. *P < 0.05;
action with C/EBPα. 293T cells were transfected with the indicated
jected to immunoprecipitation using anti–c-Myc followed by
s is shown. The locations of the AD domain and the bZIP domain are
tion with HBZ. 293T cells were transfected with mycHis-HBZ and
tes were subjected to IP using anti-FLAG followed by IB using anti–His.
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action with HBZ is mediated by the bZIP segment of
C/EBPα (Figure 4E).
C/EBPα is overexpressed in ATL
We next checked the expression level of CEBPA mRNA
and protein in ATL. Three healthy donors and six ATL
patients with different age and disease status were
included in this study. CD4 positive cells were isolated
from PBMCs of the clinical samples, and real-time PCR
was performed to analyze the expression of CEBPA
mRNA. Compared with normal T cells, all ATL patients
constitutively expressed CEBPA transcript. Noticeably,
the three youngest patients who suffered from acute
ATL expressed higher levels of CEBPA compared with
the other three patients (Figure 5A). Immunohistochem-
ical analysis of lymph nodes of ATL patients showed that
lymphoma cells indeed expressed C/EBPα (Figure 5B).
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Figure 5 C/EBPα was overexpressed in ATL. (A) High expression of CEB
donors and ATL patients, and real-time PCR was performed to analyze the
patients. (B) Determination of C/EBPα in ATL patient by immunohistochem
was subjected to immunostaining with anti-C/EBPα antibody. (C) CEBPA is
CEBPA mRNA in HTLV-1-negative (open bars) and HTLV-1-positive cell lines
HTLV-1 cell lines. Celll lystes of HTLV-1-negative and HTLV-1-positive cell linCEBPA in HTLV-1-infected cell lines compared with
noninfected ones (Figure 5C). Moreover, high levels
of C/EBPα protein were detected in ATL cell lines
(Figure 5D).
C/EBPα expression is induced by HBZ
It is well established that HBZ is the only viral gene that
remains intact and is constitutively expressed in all ATL
cases [34]. Considering that the level of C/EBPα is
elevated in ATL and HTLV-1 associated cell lines, we
evaluated whether HBZ controlled the excess expression
of C/EBPα. As shown in Figure 6A, the CEBPA gene
was upregulated in Kit 225 cells, which stably express
HBZ. To investigate HBZ-mediated enhancement of
CEBPA expression in vivo, we studied the level of CEBPA
in splenic CD4+ T cells from HBZ transgenic mice. Con-
sistently, expression of CEBPA was upregulated in HBZ
transgenic mice as observed in vitro (Figure 6B). We






PA in ATL. CD4 positive cells were isolated from PBMCs of healthy
expression of CEBPA mRNA. H indicates healthy donors, P indicates ATL
ical analysis. Lymph nodes of an ATL patient was fixed, and C/EBPα
overexpressed in HTLV-1 associated cell lines. Quantitative analysis of
(black bars) by real-time PCR. (D) Overepression of C/EBPα protein in























































































Figure 6 HBZ induced C/EBPα expression. Total RNA was extracted from control or HBZ-expressing Kit 225 (A) and CD4+ cells of HBZ
transgenic mice (B). Real-time PCR was performed to analyze the expression of CEBPA mRNA. (C) HBZ activated transcription of the CEBPA
promoter. 293T cells were transfected with the C/EBPα reporter plasmid with or without the HBZ-expressing plasmid. Luciferase activity was
measured 48 hours after transfection. (D) HBZ binds to the C/EBPα promoter. After transfection with mycHis-HBZ and C/EBPα reporter vector for
48 hours, 293T cells were chromatin immunoprecipitated by anti–c-Myc antibody. The precipitated DNAs and 1% of the input cell lysates were
amplified by the specific primers for CEBPA promoter.
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promoter region was cloned into the pGL4.10 reporter
vector and a luciferase assay was performed. As shown in
Figure 6C, HBZ enhanced transcription from the CEBPA
promoter. In addition, a chromatin immunoprecipitation
assay detected HBZ bound to the CEBPA promoter
(Figure 6D). These results collectively indicate that the
enhanced induction of CEBPA expression by HBZ can be
attributed, at least in part, to the association of HBZ with
the CEBPA promoter.HBZ overcomes C/EBPα-mediated suppression of T-cell
proliferation
Previous studies have shown that C/EBPα inhibits cell
proliferation and induces cell cycle arrest [17]. We
confirmed that the growth of mouse CD4+ T cells was
inhibited by enforced expression of C/EBPα (Figure 7A).
To address whether HBZ could affect cell proliferation
by suppressing C/EBPα signaling, we overexpressed
HBZ and C/EBPα in primary mouse CD4+ T cells.









































































































Figure 7 HBZ overcame the C/EBPα-mediated growth suppression. (A) Mouse CD4+CD25- T cells were transduced with pGCDNsamI/GFP
vector encoding C/EBPα, or with empty vector. At three days after infection, cell proliferation was analyzed by flow cytometry. (B) Mouse
CD4+CD25- T cells were transduced with pGCDNsamI/NGFR vector encoding HBZ together with pGCDNsamI/GFP-C/EBPα. Cells were stained with
specific antibody at the time points indicated, and cell growth was detected by flow cytometry. Representative data from three independent
experiments are shown. (C) HBZ modulated the expression of selected C/EBPα target genes. Total RNA was extracted from samples from the
experiment of Figure 7B. The level of MYC, FLIP, IFN-γ, BCL2, DHFR, E2F1, PER2, CDKN1A, IL6, IL4, PCNA, CDK2, β-actin, CEBPA, and HBZ mRNA were
analyzed by semiquantitative RT-PCR. (D) Transcriptional changes of selected C/EBPα target genes in CD4+ thymocytes from HBZ transgenic mice.
After stimulating the cells with PMA plus ionomycin, the levels of MYC, FLIP, E2F1, PER2, IL6, PCNA, β-actin, CEBPA, and HBZ mRNA were analyzed
by semiquantitative RT-PCR.
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regardless of C/EBPα. We next studied the effect of
HBZ on transcription of C/EBPα-specific target genes
using mouse naïve T cells expressing HBZ. Previous
reports showed that C/EBPα suppressed cell proliferation
by inhibiting the expression of E2F1, DHFR, and PCNA.
When co-expressed with C/EBPα, HBZ enhanced E2F1,
DHFR, PCNA, FLIP, BCL2, IL6, and suppressed IL4 and
IFN-γ (Figure 7C). This indicated that HBZ overcame the
suppressive effect of C/EBPα on its target genes, leading
to the cell growth. To investigate HBZ-mediated suppres-
sion of C/EBPα signaling in vivo, we studied the expres-
sion of C/EBPα-specific target genes in thymus CD4+ cells
from HBZ transgenic mice. As shown in Figure 7D,
expression of HBZ was associated with enhanced
transcription of CEBPA, E2F1, PCNA, and IL6 genes and
suppression of FLIP gene; such effects were consistent
with the observation in HBZ transfected naïve T cells.
There results together indicate that HBZ supports the
proliferation of T cells through dysregulation of C/EBPα
signaling as well as selective modulation of transcription
of C/EBPα target genes.
Discussion
After transmission, HTLV-1 increases its viral copy
number by clonal proliferation of infected cells and
results in the onset of ATL [5,35]. In this strategy, Tax
was thought to play a critical role in increasing the
number of HTLV-1-infected cells by promoting prolifer-
ation and inhibiting apoptosis [36,37]. However, because
Tax is the major target of cytotoxic T lymphocytes
(CTLs), it is frequently inactivated by genetic and
epigenetic modifications [5,38]. Therefore, HTLV-1 has
evolved mechanisms to maintain cell survival in a Tax-
independent manner. We have reported that HBZ,
which is consistently expressed in ATL, promotes the
proliferation of T-lymphocytes in vitro, and increases
splenic CD4+ T-cells in HBZ transgenic mice, indicating
a role for HBZ, like tax, in the proliferation of HTLV-1
infected cells [7,31]. So far, the mechanism by which
HBZ promotes proliferation of leukemic cells has not
been well elucidated. Accumulating evidence shows that
C/EBPα possesses the ability to arrest cell proliferation
through upregulation of CDKN1A (p21) as well as direct
inhibition of E2F [39]. We firstly present evidence that
C/EBPα is highly expressed in ATL. However, C/EBPα’s
growth-suppression function is impaired by HBZ, result-
ing in the proliferation of ATL cells despite C/EBPα
expression. It is thus likely that HBZ may support the
proliferation of HTLV-1 infected cells, whereas other
mechanisms, which include dysregulation of C/EBPα
signaling and selectively modulate C/EBPα target gene
expression. In support of our hypothesis, we showed in
this study that HBZ enhanced the expression of E2F1,PCNA, and DHFR genes in C/EBPα-expressing cells and
did not interfere with MYC, CDKN1A, and CDK2 ex-
pression, contrary to the effect of C/EBPα alone [7].
Apart from the growth suppression function, C/EBP
family proteins have oncogenic properties [17,21].
Consistent with our findings, recent studies reported
that overexpression of C/EBPα occurs in cancer, such as
B precursor acute lymphoblastic leukemia (ALL) and a
subset of human hepatocellular carcinomas (HCCs)
[22,40]. Importantly, C/EBPα induces BCL2 and FLIP
gene expression in cooperation with NF-κB p50, allow-
ing cancer cells to escape apoptosis [23]. We showed
here that C/EBPα was overexpressed in ATL, whereas its
growth-suppressive function was impaired by the effect
of HBZ. In this regard, it is meaningful to raise the ques-
tion: why do ATL cells need high levels of C/EBPα? It
has been reported that HBZ suppressed apoptosis of
HTLV-1 infected cells, while the underlying mechanism
is still unknown. As shown in Figure 7C, HBZ selectively
suppressed the level of C/EBPα target genes which
related with cell growth, but did not inhibit the C/EBPα-
induced expression of anti-apoptotic genes including
BCL2 and FLIP, suggesting that HBZ may fulfill its
anti-apoptotic function through dysregulation of C/EBPα
signaling.
Immunodeficiency in ATL patients is pronounced, and
results in frequent opportunistic infections by various
pathogens [41,42]. As a mechanism of this immunodefi-
ciency, HBZ has been shown to inhibit CD4 T-cell
responses, resulting in impaired host immunity in vivo
[31,43]. Further study demonstrated that HBZ transgenic
mice, which expressed excess amount of C/EBPα, were
vulnerable to opportunistic pathogens [31]. It was re-
ported that a population of PD-1+ memory phenotype
CD4+ T cell underlies the global depression of the T cell
immune response, and such features are attributable to
an unusual expression of C/EBPα [44]. Like C/EBPα,
C/EBPβ acts as a master regulator of the tolerogenic
and immunosuppressive environment induced by cancer
[45]. Thus, our results now open the possibility that HBZ
may induce the expression of C/EBPα, leading to im-
munodeficiency in ATL, and perhaps to oncogenesis.
Further studies on C/EBP signaling in ATL are necessary
to clarify its roles.
Many viruses have developed distinct strategies to
modulate C/EBPα signaling using their own viral pro-
teins. Examples include hepatitis B virus pX; Epstein-
Barr virus BZLF; as well as human immunodeficiency
virus TAT and Vpr [46-48]. Like HBZ, the HBV pX and
EBV BZLF protein prevent C/EBP-mediated activation
by interacting directly with C/EBP family members.
Similar upregulation of C/EBP expression has been
reported for other viruses, including hepatitis C virus,
Kaposi’s sarcoma-associated herpes virus, and human
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that dysregulation of C/EBP pathways are common
among different viruses, suggesting that these activities
are critical for viral persistence and oncogenesis.
Accumulating evidences show that HBZ’s oncogenic
function can be attributed, at least in part, to its selective
regulation of multiple signaling pathways in ATL
[13-15,30,31]. For example, HBZ inactivates classical
NF-κB signaling without inhibiting the alternative path-
way, helping cells to evade senescence and supporting
cell proliferation [13,52]. Similarly, the negative effects
of transcription factors which include ATF3, Wnt5a, and
Smad3, were impeded by HBZ, leaving these factors to
elude host immune attack and promote cell proliferation
[14,15,30]. In this study, we found that HBZ selectively
impaired the growth suppression function of C/EBPα,
rendering the immunosuppressive and anti-apoptotic
effect of C/EBPα predominant. HTLV-1 might escape
from host immune surveillance and induce cell prolifera-
tion by thus selectively modulating signaling pathways,
promoting viral reproduction, and also ATL.
It has been reported that HBZ is not able to form
stable homodimers and is therefore dependent on
heterodimerization with other proteins to control gene
transcription [53]. Thus, the function of HBZ depends,
at least in part, on its binding partner. Indeed, HBZ
selectively suppressed the classical NF-κB pathway through
inhibiting DNA binding of p65 as well as PDLIM2-
dependent p65 degradation. The specificity of PDLM2 E3
ligase in targeting p65 protein, but not p52 of the alterna-
tive pathway, may possibly explain why HBZ selectively
inhibits the classical pathway of NF-κB [13]. Similarly, we
showed in this study that HBZ inhibited C/EBPα signaling
via recruitment of Smad3. Because the association with
Smad proteins is crucial for C/EBPα in determining its
target genes as well as transcriptional outcome, it is likely
that the function of HBZ-Smad3-C/EBPα complexes
depends on the capacity of HBZ to recruit Smad3-C/EBPα
heterodimers onto the DNA target [32,54].
Conclusion
We showed that HBZ impaired the growth suppression
function of C/EBP signaling by physically interacting
with C/EBPα. HTLV-1 may take advantage of this mech-
anism to allow the infected cells to proliferate in vivo.
Methods
Cell culture, mice, and clinical samples
293T, Hela, and HepG2 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and antibiotics. HTLV-1
immortalized cell lines (MT-4), ATL cell lines (MT-1,
ATL-2, ATL-43T, ED, and TL-Om1), and T-cell lines
not infected with HTLV-1 (Jurkat) were cultured inRPMI 1640 supplemented with 10% FBS and antibiotics.
Kit 225 cells stably expressing HBZ were maintained as
described previously [7]. C57BL/6J mice were purchased
from CLEA Japan (Tokyo, Japan). Transgenic HBZ mice
expressing HBZ specifically in CD4+ cells have been de-
scribed [55]. Peripheral blood mononuclear cells (PBMCs)
were isolated from ATL patients (n = 6), and healthy
volunteers (n = 3). Details of clinical samples are shown in
Additional file 3: Table S1.The study of clinical samples
was conducted according to the principles expressed in
the Declaration of Helsinki and approved by the Institu-
tional Review Board of Kyoto University (844 and E-921).
All patients provided written informed consent for the
collection of samples and subsequent analysis.
Plasmids
The pC/EBP-Luc construct contains three tandem C/EBP
binding sites and was purchased from Stratagene
(Heidelberg, Germany). phRL-TK was purchased from
Promega (Madison, WI). Reporter vector pLTR-Luc as
well as expression plasmids for Tax, Smad3, HBZ,
and HBZ deletion mutants were prepared as previously
described [7,13,14]. Expression vectors for C/EBPα and its
deletion mutants were generated by PCR.
Luciferase assay
Jurkat cells were plated on 6-well plates at 3.5×105 cells
per well. After 24 hours, cells were transfected with the
indicated luciferase plasmid DNA. Forty-eight hours
after transfection, a luciferase reporter assay was per-
formed as previously described [13]. For the C/EBPα
reporter assay, the CEBPA gene promoter was cloned
into the pGL4.1 vector. Luciferase values were normal-
ized to renilla luciferase and expressed as the mean of a
triplicate set of experiments ± SD.
Immunoprecipitation and immunoblotting
293Tcells were transfected with the indicated combinations
of expression vectors by TransIT-LT1 (Mirus, Madison,
WI). Tagged proteins were immunoprecipitated by anti–c-
Myc (clone 9E10, Sigma-Aldrich, St Louis, MO), anti-HA
(12CA5, Roche, Mannheim, Germany) or anti-FLAG M2
(Sigma-Aldrich) antibodies, and analyzed by Western blot.
Serial immunoprecipitation was performed as described
previously [14]. Other antibodies used were as follows:
anti-mouse immunoglobulin G (IgG), and anti-rabbit IgG
were from GE Healthcare Life Sciences, and anti-C/EBPα
from Santa Cruz Biotechnology (Santa Cruz, CA).
Immunofluorescence analysis
Hela cells were transfected with expression vectors using
TransIT-LT1. Forty-eight hours after transfection, HBZ
protein was detected using anti–c-MYC Cy3 (clone 9E10,
Sigma-Aldrich). C/EBPα was detected using anti–FLAG-
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488 antibody (Invitrogen, Carlsbad, CA). Fluorescence
was observed with a confocal microscope system (Leica,
Wetzlar, Germany) as described previously [14].
Chromatin immunoprecipitation assay
293T cells were transfected with the HBZ and C/EBPα ex-
pression vectors together with pC/EBP-Luc reporter vector.
Forty-eight hours after transfection, chromatin immuno-
precipitation (ChIP) assay was performed as previously de-
scribed [14]. Precipitated DNA was amplified by PCR using
primers specific for the pC/EBP-Luc plasmid. Sequences
for the primer set were 5′-TCACTGCATTCTAGTTG
TGG-3′ and 5′-CCATCCTCTAGAGGATAGA-3′.
Semiquantitative RT-PCR and quantitative real-time PCR
Total RNA was isolated using Trizol Reagent (Invitrogen)
according to the manufacturer’s instructions. We reverse
transcribed total RNA into single-stranded cDNA with
SuperScript III reverse transcriptase (Invitrogen). For
semiquantitative PCR, cDNA was amplified by increasing
PCR cycles using forward (F) and reverse (R) primers spe-
cific to the target genes. In the real-time PCR experiment,
cDNA product was quantified with Power SYBR Green
PCR Master Mix and StepOnePlus Real Time PCR
System (Life technologies). Endogenous β-actin mRNA
was quantified to normalize the amount of cDNA load.
The specific primers used can be found in Additional
file 4: Table S2.
Immunohistochemical analyses
The tissue specimens were obtained from human lymph
nodes filed at the Department of Pathology at Kurume
University. Tissue samples were fixed in 10% formalin in
phosphate buffer and then embedded in paraffin and
analyzed by immunohistochemical methods to deter-
mine C/EBPα expression. Images were captured using a
Provis AX80 microscope equipped with an OLYMPUS
DP70 digital camera, and detected using a DP manager
system (Olympus, Tokyo, Japan). The study of clinical
samples was approved by the local research ethics
committee of Kurume University.
Small interfering RNA (siRNA) transfection
siRNA targeted to human Smad3 was synthesized accord-
ing to a previous report [56]. HepG2 cells were transfected
with expression vectors and siRNA using TransIT-LT1
according to the manufacturer’s instructions. RT-PCR
detected SMAD3 48 hours after transfection.
Retroviral constructs and transduction
pGCDNsamI/NGFR-HBZ and pGCDNsamI/GFP-C/EBPα
retroviral constructs were generated by cloning HBZ
and C/EBPα cDNA into the pGCDNsamI/NGFR andpGCDNsamI/GFP vectors respectively. Transfection of
Plat-E packaging cell line was performed as described
[57]. Mouse splenocytes were enriched for CD25-CD4+
cells with a CD4 T lymphocyte enrichment set (BD
Biosciences) with the addition of biotinylated anti-
CD25 antibody (BD Biosciences), and activated by
APCs in the presence of anti-CD3 antibody and
human rIL-2 in 12-well plates. After 24 hours, acti-
vated T cells were transduced with viral supernatant and
polybrene, and centrifuged at 3,000 rpm for 60 minutes.
Cells were subsequently cultured in medium supple-
mented with rIL-2.Flow cytometric analysis
Murine cells were washed with PBS containing 1% FBS.
After centrifugation, cells were treated with APC-conju-
gated anti-human NGFR antibody (BD Biosciences) for 30
minutes. After being washed with PBS, the cells were
analyzed with a flow cytometer (BD FACSCanto II, BD
Biosciences).Statistical analyses
Statistical analyses were performed using the unpaired
Student t test.Additional files
Additional file 1: Figure S1. C/EBPα did not influence HBZ expression.
293T cells were transfected with expression vector of HBZ and increasing
amounts of C/EBPα. After 48 hours, the cell lysates were subjected to
Western blot.
Additional file 2: Figure S2. HBZ, Smad3, and C/EBPα formed a ternary
complex. mycHis-HBZ, FLAG-Smad3, and HA-C/EBPα were cotransfected
into 293T cells. After 48 hours, cell lysates were subjected to immunopre-
cipitation using anti–c-Myc or anti-FLAG followed by immunoblotting
using anti-FLAG, anti-His, and anti-HA antibody.
Additional file 3: Table S1. List of healthy donors and ATL patients. The
information of six ATL patients and three healthy volunteers are listed.
Additional file 4: Table S2. List of primers for semi-quantitative RT-PCR
and quantitative real-time PCR. We performed semi-quantitative RT-PCR
and quantitative real-time PCR using the following primers.
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